Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $22.2 million.

  • Janux Therapeutics' Accumulated Expenses rose 7014.28% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year increase of 7014.28%. This contributed to the annual value of $11.7 million for FY2024, which is 5816.98% up from last year.
  • Latest data reveals that Janux Therapeutics reported Accumulated Expenses of $22.2 million as of Q3 2025, which was up 7014.28% from $16.0 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Accumulated Expenses ranged from a high of $22.2 million in Q3 2025 and a low of $2.0 million during Q3 2021
  • For the 5-year period, Janux Therapeutics' Accumulated Expenses averaged around $8.6 million, with its median value being $7.6 million (2023).
  • As far as peak fluctuations go, Janux Therapeutics' Accumulated Expenses soared by 40319.57% in 2021, and later tumbled by 2490.63% in 2024.
  • Quarter analysis of 5 years shows Janux Therapeutics' Accumulated Expenses stood at $3.8 million in 2021, then soared by 116.43% to $8.2 million in 2022, then fell by 9.68% to $7.4 million in 2023, then skyrocketed by 58.17% to $11.7 million in 2024, then surged by 89.63% to $22.2 million in 2025.
  • Its Accumulated Expenses stands at $22.2 million for Q3 2025, versus $16.0 million for Q2 2025 and $13.3 million for Q1 2025.